Cullinan Therapeutics Inc.
Clinical trials sponsored by Cullinan Therapeutics Inc., explained in plain language.
-
New lupus drug trial aims to tame immune system
Disease control Recruiting nowThis early-stage study tests a new drug, CLN-978, in 24 people with moderate to severe lupus. The goal is to see if it is safe and can help control the disease by reducing certain immune cells. Participants receive the drug as a shot under the skin.
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
New Immune-Boosting drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-049 in about 60 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals are …
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 08:01 UTC
-
New shot for Sjogren's disease enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug, CLN-978, given as a shot under the skin for people with active, moderate to severe Sjogren's disease. The main goal is to check safety and side effects, and it will also measure how the drug works in the body and affects immune cells. Abou…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC